J&J joins blockbuster HIV combo race with newly approved 4-in-1 pill
Sliding into the HIV combo rivalry between Gilead and GSK, J&J has notched an approval for a 4-in-1 pill based on its antiretroviral med darunavir.
To be marketed as Symtuza, the drug is a single daily pill that combines J&J’s darunavir (800mg) with cobicistat (150 mg), emtricitabine (200 mg) and tenofovir alafenamide (10 mg) from Gilead. The latter two form the backbone combination for Gilead’s blockbuster triplet Biktarvy — with 2022 projected sales at $3.71 billion — while cobicistat is a pharmacokinetic enhancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
